A STUDY TO DETERMINE THE EXCRETION BALANCE, PHARMACOKINETICS, METABOLISM AND ABSOLUTE ORAL BIOAVAILABILITY OF A SINGLE ORAL DOSE OF [14C]-LABELED IDASANUTLIN AND AN INTRAVENOUS TRACER DOSE OF [13C]-LABELED IDASANUTLIN IN A SINGLE COHORT OF PARTICIPANTS WITH SOLID TUMORS (MALIGNANCIES):